Development · 21 Sep 2026

In Q1FY27, Sun Pharma's consolidated revenue from operations rose 10.5 per cent year-over-year to ₹15,300 crore, driven by strong growth in the India formulations business and sustained momentum in the Innovative Medicines portfolio.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

thehindubusinessline.com21 Sep 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Sun Pharmaceutical Industries

₹1,801.00

▼ -0.86%

Close (EOD), as of 1 Oct 2026 · source

Sun Pharmaceutical Industries: results, dividends, orders, the full cited record →

More on Sun Pharmaceutical Industries

US pharma tariff relief has different implications for Indian drugmakers depending on whether their US business is built around patented medicines, generics, complex injectables or contract manufacturing.

2 Oct 2026 · 1 publisher

Sun Pharmaceutical Industries is planning to raise around 100 billion rupees ($1.04 billion) via a rupee-denominated debt sale to partly fund a bridge loan it took to acquire US healthcare firm Organon & Co.

30 Sep 2026 · 2 publishers

Sun Pharmaceutical Industries Ltd announced an exclusive licensing, commercialisation and manufacturing agreement with LIB Therapeutics Inc for lerodalcibep, a PCSK9 inhibitor, across markets outside the United States and China.

29 Sep 2026 · 7 publishers

Eli Lilly has secured marketing approval for Olumiant (baricitinib) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA).

29 Sep 2026 · 1 publisher

Sun Pharmaceutical Industries is voluntarily recalling Lidocaine ointment and Nystatin cream in the US due to quality issues identified during routine testing.

26 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.